BT1718
Solid Tumors (targeting MT1-MMP)
Phase 1/2aCompleted/Terminated
Key Facts
Indication
Solid Tumors (targeting MT1-MMP)
Phase
Phase 1/2a
Status
Completed/Terminated
Company
About Bicycle Therapeutics
Bicycle Therapeutics aims to become a world-leading solid tumor medicines company by leveraging its proprietary Bicycle® platform to create precision-guided therapeutics. Its core technology enables the rapid discovery and development of constrained peptides with high affinity and selectivity for challenging targets. The company is progressing multiple clinical-stage oncology assets and has established creative collaborative relationships to expand its technology into anti-infective, cardiovascular, and CNS diseases.
View full company profile